Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477156 | 0.84 | KDM4E (0.56) | CYP1A2CYP3A4CYP2C19KDM4EL3MBTL1 | |
| SCHEMBL29209505 | 0.84 | ATM (0.53) | CYP1A2CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL1659844 | 0.82 | CYP2C19 (0.61) | CYP1A2CYP3A4CYP2C19KDM4EL3MBTL1 | |
| SCHEMBL5094634 | 0.81 | KDM4E (0.67) | CYP1A2CYP3A4CYP2C19KDM4EL3MBTL1 | |
| SCHEMBL5160500 | 0.80 | HCAR2 (0.39) | KDM4EHCAR2LMNA | |
| SCHEMBL308788 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C19KDM4EL3MBTL1 | |
| SCHEMBL3825532 | 0.78 | KDM4E (0.59) | CYP1A2CYP3A4CYP2C19KDM4EL3MBTL1 | |
| SCHEMBL2316790 | 0.78 | MEN1 (0.48) | CYP1A2CYP3A4CYP2C19KDM4EL3MBTL1 | |
| SCHEMBL6133214 | 0.76 | POLB (0.63) | KDM4ESMN1; SMN2HTTMAPTPOLB | |
| SCHEMBL31585402 | 0.76 | KDM4E (0.53) | CYP1A2CYP3A4CYP2C19KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027029-A | Preparation method and application of Anfonafate and analogues thereof | 新疆大学 | 2024-05-14 | — | — | CN | disclosed |
| EP-1581535-B3 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-1581535-B9 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-7317009-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| CN-100349895-C | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC (JP) | 2007-11-21 | — | — | CN | disclosed |
| EP-1581535-B1 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-7153854-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| CN-1759117-A | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC (JP) | 2006-04-12 | — | — | CN | disclosed |
| EP-1581535-A1 | PYRROLOPYRIDAZINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-20050075342-A1 | Pyrrolopyridazine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-07 | — | — | US | disclosed |
| WO-2004063197-A1 | PYRROLOPYRIDAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075342-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | CYP1A2 367/4885CYP3A4 202/4885CYP2C19 867/4885 |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | CYP1A2 367/4885CYP3A4 202/4885CYP2C19 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.